Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders.
about
Prognostic Significance of Serum Alkaline Phosphatase Level in Osteosarcoma: A Meta-Analysis of Published DataImprovement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup.Osteosarcoma Overview.Osteosarcoma: Diagnostic dilemmas in histopathology and prognostic factors.Clinical analysis of osteosarcoma patients treated with high-dose methotrexate-free neoadjuvant chemotherapy.Characterization of localized osteosarcoma of the extremity in children, adolescents, and young adults from a single institution in South Texas.Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma: 63 patients with a minimum follow-up of 4 years.EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatmentPrognostic factors and treatment results of high-grade osteosarcoma in norway: a scope beyond the "classical" patient.The relation of tumour necrosis and survival in patients with osteosarcomaHigh dose methotrexate chemotherapy: pharmacokinetics, folate and toxicity in osteosarcoma patients.Perioperative chemotherapy in the treatment of osteosarcoma: a 26-year single institution review.Serum tumor markers in pediatric osteosarcoma: a summary review.Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials.Pediatric osteosarcoma: a 35-year experience in Slovenia.Chondroblastic osteosarcoma secondary to fibrosarcoma: A case report and literature reviewAssociation of MMP-2 expression and prognosis in osteosarcoma patients.Adenovirus-mediated p53 tumor suppressor gene therapy of osteosarcoma.Patterns of care and survival for patients aged under 40 years with bone sarcoma in Britain, 1980-1994.A Phase II Study of Docetaxel for the Treatment of Recurrent Osteosarcoma.Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies.Risk factors for hematological toxicity of chemotherapy for bone and soft tissue sarcomaCirculating Natural IgM Antibodies Against Angiogenin in the Peripheral Blood Sera of Patients with Osteosarcoma as Candidate Biomarkers and Reporters of TumorigenesisCurrent status and perspectives regarding the treatment of osteo-sarcoma: chemotherapyIntra-patient dose escalation in Ewing's sarcoma treated with vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide and etoposide: a retrospective review.Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group.How can survival be improved in localized osteosarcoma?18F-FDG PET response to neoadjuvant chemotherapy for Ewing sarcoma and osteosarcoma are different.Incidence, epidemiology and treatment results of osteosarcoma in Finland - a nationwide population-based study.Clinical relations of methotrexate pharmacokinetics in the treatment for pediatric osteosarcoma.Developing a prognostic model for patients with localized osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate: A single-center experience of 237 patients.A study of 853 high grade osteosarcomas from a single institution-Are outcomes in Indian patients different?Telangiectatic osteosarcoma: a review of 87 cases.Functional outcome after surgery in patients with bone sarcoma around the knee; results from a long-term prospective study.Referral patterns, treatment and outcome of high-grade malignant bone sarcoma in Scandinavia--SSG Central Register 25 years' experience.Long non-coding RNA XIST regulates PDCD4 expression by interacting with miR-21-5p and inhibits osteosarcoma cell growth and metastasis.The Scandinavian Sarcoma Group: 30 years' experience.Clinical efficacy of preoperative chemotherapy with or without ifosfamide in patients with osteosarcoma of the extremity: meta-analysis of randomized controlled trials.Osteosarcoma in Finland from 1971 through 1990: a nationwide study of epidemiology and outcome.Chemoradiotherapy in the treatment of inoperable high-grade osteosarcoma.
P2860
Q26775998-2EE0AA10-0999-4DD5-9926-01AEDF2D2A8BQ33373879-40EBCA64-476D-4A68-AFB1-D0F273797A3DQ33725511-BF72E2E9-A615-4F70-ABA1-4818147E5104Q33735680-833EB723-2847-4BF0-AB6E-21D5A0A31B9BQ34305928-7ED81BEB-6C51-4E78-9B5D-E5C6CE7698E8Q34464245-1EB6C110-C9EF-41C4-9694-4B46932BB110Q34627906-3AF1C38D-D39F-495D-A0C3-732B52937396Q35005741-1FBE9C72-0A75-4B4D-9F06-A664BCC04D29Q35138344-E86A527D-7D2C-4840-B160-AF9DDB848ABAQ35574435-D1FB2C23-E1D8-420C-93C5-DA3DACFE6327Q35640471-51474B42-2BD0-47EA-B5AD-F9D52967AF22Q35848126-244510D1-5879-48B7-99DB-516142FB2884Q35984687-C8AA334B-50A9-4561-A2E1-3B38522B83C4Q35988850-B8FEA907-0E37-44F0-9A24-5CD3853932DBQ36195151-84A09BE6-4250-4C12-8258-B4508A0323A3Q36336179-BA01D3DE-38E2-496B-89EF-2DB149B5509BQ36464735-DB96589E-76A6-4319-B7EF-72509B2AA5B4Q36496709-1A6DEE66-F5D2-4BED-850E-4AD81C0F7D1FQ36613417-40C5EA1A-1DDD-4283-9CDD-31E681794A22Q36674440-8D9672FD-C0EB-4153-AE70-AEAB43E99F5EQ36731426-C893C964-7E54-450C-B8CA-46F1B3CB7485Q36918707-579C9BBC-3B16-430E-B90D-6C127C14C7F4Q37198133-748B5722-FD67-4FD8-BC41-E8B7E78D1B26Q37265109-D393F14D-2E67-48DF-BE30-DED50E69C9F8Q37400113-CD2758A1-F7B8-4B90-93FC-FE0D8CF5D94BQ37439345-DB049DE7-ABFC-43C0-867A-D5641708C7C3Q37782098-1D11181F-4642-44FD-9A4C-678E13F57F04Q37836534-6B40DCB8-77B0-4AF4-98AB-8F383D551DAAQ37948876-39162FCC-C495-4F34-B6DA-C143746F498EQ38015163-11E4FB83-9EC2-4A7B-A08E-A95D1BF10F45Q38588532-8090ED91-74C6-4A3B-8879-88FE70AE679EQ38612300-3F0B32D1-FC0E-418E-90D7-A837688D5E1DQ38911783-D968402A-97C3-40B4-9C15-1EDA27D1834AQ40254834-CDC171A7-29A5-4649-999B-1655579E11BDQ40414026-CBB2C4CB-76FE-45B4-B57B-3447685E397FQ42378706-32E28ED8-C171-4087-B9F9-C8CD3AFC2978Q43589203-7BDB6FA1-97AE-4586-B62E-8594F9412D03Q43654763-ABA02039-36ED-4624-A6AC-14E69D350879Q44044741-56D5D576-E8FC-42C6-9096-AD4F708FDD22Q44582217-55B7AC6C-7729-4EEC-BC59-AB1061D4186C
P2860
Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Scandinavian Sarcoma Group Ost ...... poor histological responders.
@ast
Scandinavian Sarcoma Group Ost ...... poor histological responders.
@en
Scandinavian Sarcoma Group Ost ...... poor histological responders.
@nl
type
label
Scandinavian Sarcoma Group Ost ...... poor histological responders.
@ast
Scandinavian Sarcoma Group Ost ...... poor histological responders.
@en
Scandinavian Sarcoma Group Ost ...... poor histological responders.
@nl
prefLabel
Scandinavian Sarcoma Group Ost ...... poor histological responders.
@ast
Scandinavian Sarcoma Group Ost ...... poor histological responders.
@en
Scandinavian Sarcoma Group Ost ...... poor histological responders.
@nl
P2093
P1476
Scandinavian Sarcoma Group Ost ...... r poor histological responders
@en
P2093
A E Stenwig
G Follerås
P304
P356
10.1016/S0959-8049(02)00747-5
P50
P577
2003-03-01T00:00:00Z